|
US5023321A
(en)
|
1982-12-13 |
1991-06-11 |
Howard Florey Institute Of Experimental Physiology & Medicine |
Molecular cloning and characterization of a further gene sequence coding for human relaxin
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4682195A
(en)
|
1985-09-30 |
1987-07-21 |
General Electric Company |
Insulated gate device with configured emitter contact pad
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US4835251A
(en)
|
1986-06-23 |
1989-05-30 |
Genetech, Inc. |
Method of chain combination
|
|
EP0266032A1
(en)
|
1986-08-29 |
1988-05-04 |
Beecham Group Plc |
Modified fibrinolytic enzyme
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5302523A
(en)
|
1989-06-21 |
1994-04-12 |
Zeneca Limited |
Transformation of plant cells
|
|
US7705215B1
(en)
|
1990-04-17 |
2010-04-27 |
Dekalb Genetics Corporation |
Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
|
|
US5550318A
(en)
|
1990-04-17 |
1996-08-27 |
Dekalb Genetics Corporation |
Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
|
|
US5322783A
(en)
|
1989-10-17 |
1994-06-21 |
Pioneer Hi-Bred International, Inc. |
Soybean transformation by microparticle bombardment
|
|
US5484956A
(en)
|
1990-01-22 |
1996-01-16 |
Dekalb Genetics Corporation |
Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
|
|
US5466468A
(en)
|
1990-04-03 |
1995-11-14 |
Ciba-Geigy Corporation |
Parenterally administrable liposome formulation comprising synthetic lipids
|
|
US5384253A
(en)
|
1990-12-28 |
1995-01-24 |
Dekalb Genetics Corporation |
Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
|
|
US5399363A
(en)
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
WO1993004169A1
(en)
|
1991-08-20 |
1993-03-04 |
Genpharm International, Inc. |
Gene targeting in animal cells using isogenic dna constructs
|
|
US5610042A
(en)
|
1991-10-07 |
1997-03-11 |
Ciba-Geigy Corporation |
Methods for stable transformation of wheat
|
|
DE4204650C1
(enExample)
|
1992-02-15 |
1993-07-08 |
Hoffmeister, Helmut, Dr., 4400 Muenster, De |
|
|
DK0604662T3
(da)
|
1992-07-07 |
2008-10-20 |
Japan Tobacco Inc |
Fremgangsmåde til transformering af monocotyledon
|
|
US5702932A
(en)
|
1992-07-20 |
1997-12-30 |
University Of Florida |
Microinjection methods to transform arthropods with exogenous DNA
|
|
AU670316B2
(en)
|
1992-07-27 |
1996-07-11 |
Pioneer Hi-Bred International, Inc. |
An improved method of (agrobacterium)-mediated transformation of cultured soybean cells
|
|
DE4228457A1
(de)
|
1992-08-27 |
1994-04-28 |
Beiersdorf Ag |
Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
|
|
GB9222888D0
(en)
|
1992-10-30 |
1992-12-16 |
British Tech Group |
Tomography
|
|
US5846945A
(en)
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
JPH08506247A
(ja)
|
1993-07-09 |
1996-07-09 |
アムジェン ボールダー インコーポレイテッド |
組換えｃｔｌａ４ポリペプチドおよびその製造方法
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
WO1995011986A1
(en)
|
1993-10-27 |
1995-05-04 |
The Trustees Of Columbia University In The City Of New York |
METHOD FOR GENERATING A SUBTRACTED cDNA LIBRARY AND USES OF THE GENERATED LIBRARY
|
|
US5656610A
(en)
|
1994-06-21 |
1997-08-12 |
University Of Southern California |
Producing a protein in a mammal by injection of a DNA-sequence into the tongue
|
|
FR2722208B1
(fr)
|
1994-07-05 |
1996-10-04 |
Inst Nat Sante Rech Med |
Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
US5736524A
(en)
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
|
US5599302A
(en)
|
1995-01-09 |
1997-02-04 |
Medi-Ject Corporation |
Medical injection system and method, gas spring thereof and launching device using gas spring
|
|
IE80468B1
(en)
|
1995-04-04 |
1998-07-29 |
Elan Corp Plc |
Controlled release biodegradable nanoparticles containing insulin
|
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
US5811395A
(en)
|
1995-06-07 |
1998-09-22 |
Medical University Of South Carolina |
Relaxin analogs and derivatives methods and uses thereof
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
US5705629A
(en)
|
1995-10-20 |
1998-01-06 |
Hybridon, Inc. |
Methods for H-phosphonate synthesis of mono- and oligonucleotides
|
|
US5780448A
(en)
|
1995-11-07 |
1998-07-14 |
Ottawa Civic Hospital Loeb Research |
DNA-based vaccination of fish
|
|
US5928906A
(en)
|
1996-05-09 |
1999-07-27 |
Sequenom, Inc. |
Process for direct sequencing during template amplification
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
US5945100A
(en)
|
1996-07-31 |
1999-08-31 |
Fbp Corporation |
Tumor delivery vehicles
|
|
US5710137A
(en)
|
1996-08-16 |
1998-01-20 |
The Trustees Of Columbia University In The City Of New York |
Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
|
|
EP0955999B1
(en)
|
1996-08-19 |
2001-12-05 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Novel liposome complexes for increased systemic delivery
|
|
US5981274A
(en)
|
1996-09-18 |
1999-11-09 |
Tyrrell; D. Lorne J. |
Recombinant hepatitis virus vectors
|
|
US5846225A
(en)
|
1997-02-19 |
1998-12-08 |
Cornell Research Foundation, Inc. |
Gene transfer therapy delivery device and method
|
|
US5736167A
(en)
|
1997-02-27 |
1998-04-07 |
Chang; Hui Hwa |
Mold device for making safety shoe
|
|
EP0970128A1
(en)
|
1997-03-21 |
2000-01-12 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
|
US5994624A
(en)
|
1997-10-20 |
1999-11-30 |
Cotton Incorporated |
In planta method for the production of transgenic plants
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
ES2706547T3
(es)
|
1998-12-23 |
2019-03-29 |
Pfizer |
Anticuerpos monoclonales humanos para CTLA-4
|
|
US7589069B1
(en)
|
1999-07-12 |
2009-09-15 |
Saint Louis University |
Replication-competent anti-cancer vectors
|
|
CA2379171A1
(en)
|
1999-07-15 |
2001-01-25 |
Introgen Therapeutics, Inc. |
Methods for treatment of hyperproliferative diseases using human mda-7
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
JP4810042B2
(ja)
|
2000-01-21 |
2011-11-09 |
バイオヴェックス リミテッド |
ヘルペスウイルス株
|
|
CA2511625A1
(en)
|
2002-12-23 |
2004-07-15 |
City Of Hope |
Modified vaccinia ankara expressing p53 in cancer immunotherapy
|
|
KR100523028B1
(ko)
|
2003-02-27 |
2005-10-20 |
윤채옥 |
개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터
|
|
HRP20120845T1
(hr)
|
2003-07-02 |
2012-11-30 |
Innate Pharma |
Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
|
|
HUE033129T2
(en)
|
2003-07-24 |
2017-11-28 |
Innate Pharma Sa |
Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
|
|
US20070281041A1
(en)
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
|
JP5295568B2
(ja)
|
2005-01-06 |
2013-09-18 |
ノヴォ ノルディスク アー／エス |
Ｋｉｒ結合剤およびその使用方法
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
EP1838353A2
(en)
*
|
2005-01-21 |
2007-10-03 |
Introgen Therapeutics, Inc. |
Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
|
|
KR100747646B1
(ko)
|
2005-02-25 |
2007-08-08 |
연세대학교 산학협력단 |
데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
|
|
US20060257361A1
(en)
|
2005-04-12 |
2006-11-16 |
Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services |
Novel form of interleukin-15, Fc-IL-15, and methods of use
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
EP1934260B1
(en)
|
2005-10-14 |
2017-05-17 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
|
US20070160578A1
(en)
|
2005-12-14 |
2007-07-12 |
The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services |
Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
|
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
|
AU2008204433B2
(en)
|
2007-01-11 |
2014-03-13 |
Novo Nordisk A/S |
Anti-KIR antibodies, formulations, and uses thereof
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
EP2173378B1
(en)
*
|
2007-06-27 |
2014-03-19 |
Admune Therapeutics LLC |
Complexes of il-15 and il-15ralpha and uses thereof
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
EP2245464B1
(en)
|
2008-01-25 |
2016-12-14 |
MultiVir Inc. |
P53 biomarkers
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
CN101658670A
(zh)
|
2008-08-25 |
2010-03-03 |
中国疾病预防控制中心性病艾滋病预防控制中心 |
基于n1l和b8r基因缺失的痘苗病毒载体的艾滋病疫苗
|
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
|
DK2403951T3
(en)
|
2009-03-02 |
2016-01-11 |
Univ California |
Tumor-selective E1a and E1b adenoviral mutants
|
|
GR1006941B
(el)
|
2009-06-01 |
2010-08-27 |
Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), |
Πεπτιδικη συνθεση (peptide synthesis)
|
|
CA2769473A1
(en)
|
2009-07-31 |
2011-02-03 |
N.V. Organon |
Fully human antibodies to btla
|
|
EP2473523A2
(en)
|
2009-08-31 |
2012-07-11 |
Amplimmune, Inc. |
Methods and compositions for the inhibition of transplant rejection
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
|
EP3053932B1
(en)
|
2010-02-19 |
2020-07-22 |
Xencor, Inc. |
Novel ctla4-ig immunoadhesins
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
JP2013541497A
(ja)
|
2010-07-16 |
2013-11-14 |
エペイウス バイオテクノロジーズ コーポレイション |
癌および他の障害のための標的指向ナノ粒子
|
|
UA113280C2
(xx)
|
2010-11-11 |
2017-01-10 |
|
АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
|
|
CA2818684C
(en)
|
2010-11-22 |
2023-02-21 |
Innate Pharma Sa |
Nk cell modulating treatments and methods for treatment of hematological malignancies
|
|
EP2518071A1
(en)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Imidazopyridine derivatives as PI3K inhibitors
|
|
EP2522726A1
(en)
*
|
2011-05-12 |
2012-11-14 |
Fundació Privada Centre de Regulació Genòmica (CRG) |
Zinc finger nucleases for p53 editing
|
|
US9067997B2
(en)
|
2011-05-25 |
2015-06-30 |
Innate Pharma Sa |
Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
|
US10238698B2
(en)
|
2012-01-25 |
2019-03-26 |
Dnatrix, Inc. |
Biomarkers and combination therapies using oncolytic virus and immunomodulation
|
|
US20150072988A1
(en)
*
|
2012-03-30 |
2015-03-12 |
The Johns Hopkins University |
Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
EA201590451A1
(ru)
|
2012-08-30 |
2016-05-31 |
Эмджен Инк. |
Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки
|
|
US20150250837A1
(en)
|
2012-09-20 |
2015-09-10 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
GEP201706623B
(en)
|
2012-10-16 |
2017-02-10 |
Almirall Sa |
Pyrrolotriazinone derivatives as pi3k inhibitors
|
|
CN103110939A
(zh)
|
2012-10-23 |
2013-05-22 |
郑州大学 |
诱导肿瘤特异性免疫的疫苗及其应用
|
|
WO2014100014A1
(en)
|
2012-12-17 |
2014-06-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Super-2 complexes with antibody to augment il-2 therapy
|
|
WO2014138314A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Oncolytic virus
|
|
WO2014164942A1
(en)
|
2013-03-13 |
2014-10-09 |
The Regents Of The University Of Michigan |
Dual mek/pi3k inhibitors and therapeutic methods using the same
|
|
WO2014150056A1
(en)
|
2013-03-15 |
2014-09-25 |
Numbergun Llc |
Improvements for base64 encoding and decoding
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
CN105682683A
(zh)
|
2013-08-02 |
2016-06-15 |
阿杜罗生物科技控股有限公司 |
结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
|
|
ES2847305T3
(es)
|
2013-08-22 |
2021-08-02 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Terapias inmunooncolíticas
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
EA201690912A1
(ru)
|
2013-11-05 |
2016-10-31 |
Когнейт Биосервисис, Инк. |
Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
|
|
CN114317461A
(zh)
|
2013-11-22 |
2022-04-12 |
德那翠丝有限公司 |
表达免疫细胞刺激受体激动剂的腺病毒
|
|
WO2015082376A2
(en)
|
2013-12-03 |
2015-06-11 |
Bayer Pharma Aktiengesellschaft |
Use of pi3k-inhibitors
|
|
GB201405834D0
(en)
|
2014-04-01 |
2014-05-14 |
Univ London Queen Mary |
Oncolytic virus
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
CA2954476C
(en)
|
2014-07-10 |
2023-09-19 |
Novartis Ag |
Immune-stimulating monoclonal antibodies against human interleukin-2
|
|
ES2833425T3
(es)
|
2014-07-16 |
2021-06-15 |
Roussy Inst Gustave |
Combinación de virus oncolítico con moduladores de punto de control inmunitario
|
|
DK3552615T3
(da)
|
2014-07-16 |
2022-02-14 |
Transgene |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
AU2016251687C1
(en)
*
|
2015-04-22 |
2023-07-27 |
CureVac SE |
RNA containing composition for treatment of tumor diseases
|
|
US20190038713A1
(en)
*
|
2015-11-07 |
2019-02-07 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
JP2019513021A
(ja)
*
|
2016-03-24 |
2019-05-23 |
ナントセル，インコーポレイテッド |
ネオエピトープ提示のための配列の配置および配列
|
|
AU2018287317B2
(en)
*
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|